Developer docs
API playgroundTry for free, no card

Search company profiles

ViCentra

Full company profile

uuid00002rg

Namestring
ViCentra
Legal namestring
ViCentra B.V.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

ViCentra B.V. is a Utrecht, Netherlands-based medical device company founded in 2013 that designs, manufactures, and commercializes the Kaleido insulin patch pump system for adults with Type 1 diabetes. The flagship Kaleido pump is a compact (50x35x12.5mm, 19g), reusable, IP68-rated (1.5m for 1 hour) device available in 10 color combinations, with a 4-year warranty and a dual-wear design that supports both on-body patch and pocket wear via 5cm or 30cm tubing. The platform integrates with Diabeloop's DBLG1 and DBLG2 self-learning hybrid closed-loop algorithms and Dexcom G6/G7 continuous glucose monitors, with data managed through Diabeloop's YourLoops cloud platform and downloadable to Glooko.

ViCentra generates revenue from a Starter Kit bundle (two pumps and one handset) and high-frequency recurring consumables, including 200-unit insulin cartridges and 6mm or 9mm soft-cannula infusion sets replaced every 3 days, plus body and pump patches. The company sells exclusively through healthcare-provider prescriptions, supported by certified trainers and local medical device distributors (Mediq, TK-Pharma in Netherlands and Germany; Spezimed in Germany). Pricing is reimbursement-driven and varies by jurisdiction; Kaleido is covered by all Dutch health insurers and is eligible for reimbursement in Germany and France. The installed base grew to over 4,000 users in 2025 (doubled year-over-year), and ViCentra is preparing for U.S. market entry with an FDA filing targeted for early 2026.

ViCentra has raised approximately $200 million in total funding across a $74M Series C (December 2021, led by Partners in Equity) and a $98M Series D (initial $85M close September 2025 led by Innovation Industries, with a $13M second close in January 2026). The company employs over 200 people from 30+ nationalities and is scaling manufacturing capacity more than threefold via a partnership with Phillips Medisize to support 17,000+ users. Senior leadership includes CEO Tom Arnold (ex-Medtronic, Boston Scientific), CFO Leo Toole, CTO and co-founder Tim Oakes, and recently hired commercial leaders Karen Baxter (SVP Sales Europe, ex-Dexcom), Jay Little (VP Strategy, ex-Medtronic), and Reman McDonagh (VP Global Marketing, ex-Insulet/Medtronic/Roche/Cellnovo).

Short descriptiontext

ViCentra is a Utrecht-based medical device company that designs and commercializes the Kaleido compact, customizable insulin patch pump system for adults with Type 1 diabetes, integrating Diabeloop hybrid closed-loop algorithms and Dexcom CGM, sold via healthcare-provider prescriptions across Germany, Netherlands, and France with U.S. entry pending FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
insulin patch pump, diabetes management devices, hybrid closed loop system, continuous insulin delivery, type 1 diabetes care
Industry4 codes
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAL
Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Insulin Patch Pumps / Diabetes Management Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Insulin Pump Hardware Sales
TypeHardware Sales
Description

ViCentra generates revenue from the sale of reusable Kaleido insulin pumps that have a 4-year lifespan and come with a warranty. The Starter Kit includes two pumps and one handset.

globenewswire.com
2Consumables
TypeHardware Sales
Description

Recurring revenue from consumables including insulin cartridges (200-unit capacity, replace every 3 days), infusion sets (6mm or 9mm soft cannulas), and pump/body patches. Users purchase Top-Up Kits for additional supplies.

hellokaleido.com
3Insurance Reimbursement
TypeHardware Sales
Description

Kaleido is covered by health insurance in the Netherlands and is eligible for reimbursement in Germany and France through local healthcare systems and distributors.

hellokaleido.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Kaleido Starter Kit with reusable pump and handset
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Starter Kit includes two reusable pumps and one handset. Consumables (cartridges, infusion sets, patches) are ongoing purchases. Pricing not publicly disclosed; reimbursement varies by market and insurer.

hellokaleido.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Kaleido
Description

The Kaleido insulin patch pump system - a flexible, discreet insulin delivery device available as both standalone pump and Hybrid Closed Loop system integrated with Diabeloop's DBLG1 and DBLG2 algorithms and Dexcom CGM.

hellokaleido.com
Core offering1 text field

ViCentra designs, manufactures, and sells the Kaleido insulin patch pump system for adults with Type 1 diabetes. The reusable pump (50x35x12.5mm, 19g, 4-year warranty, IP68 waterproof) can be worn as a body patch or carried in a pocket via 5/30cm tubing and is available in 10 color combinations. The offering spans the stand-alone pump with Kaleido handset, the Hybrid Closed Loop system integrating Diabeloop's DBLG1/DBLG2 self-learning algorithms with Dexcom G6/G7 CGM, recurring consumables (200-unit cartridges and 6/9mm infusion sets replaced every 3 days), and the Kaleido Starter Kit bundle. Distribution flows through healthcare provider prescriptions, certified trainers, and local medical device distributors in Europe with health insurance reimbursement coverage.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Time in Range increased from 57.3% to 68.8% after using Kaleido Hybrid Closed Loop system
+3 more records
Product overview1 text field

ViCentra's Kaleido is a modular insulin patch pump ecosystem consisting of the Kaleido insulin pump (core device), optional Hybrid Closed Loop add-ons (DBLG1 and DBLG2 algorithms with Dexcom CGM integration), a dedicated Kaleido handset for stand-alone use, consumables (cartridges, infusion sets, patches), and a Starter Kit bundle. The system is distinguished by its compact size, customizable color options, and flexible wear options (as patch or pocket pump with tubing). The DBLG1/DGBL2 algorithms provide AI-powered automated insulin delivery, while the standalone handset includes a bolus calculator and data sync capabilities.

Product and service6 records
1Kaleido Insulin Patch Pump System
CategoryInsulin Patch Pump
Description

A compact, customizable insulin patch pump system for adults with Type 1 diabetes. Features a reusable pump with 4-year warranty, waterproof (IP68) design for 1 hour at 1.5m, 10 color combinations, dual-wear flexibility (5/30cm tubing for body patch or pocket use), and 0.05-unit pulse technology for precise dosing.

2Kaleido Hybrid Closed Loop System (DBLG1 with Dexcom G6)
CategoryHybrid Closed Loop System
Description

Automated insulin delivery system combining the Kaleido pump with Diabeloop's DBLG1 self-learning algorithm and the Dexcom G6 CGM. Continuously monitors glucose and adjusts insulin delivery in real-time. Clinical evidence shows Time in Range improved from 57.3% to 68.8%.

3Kaleido with DBLG2 and Dexcom G7
CategoryHybrid Closed Loop System
Description

Next-generation smartphone-controlled Hybrid Closed Loop system combining the Kaleido pump with Diabeloop's DBLG2 self-learning algorithm and Dexcom G7 CGM sensor.

4Kaleido Handset
CategoryPump Controller
Description

Reusable dedicated controller for the Kaleido stand-alone pump. Features bolus calculator (Kaleidoculator), 7 basal rate profiles, data upload to Glooko, and 1.5–2 day battery life per charge.

5Kaleido Consumables
CategoryPump Consumables
Description

Recurring-use consumables for the Kaleido pump system: 200-unit insulin cartridges with 5cm or 30cm tubing, 90-degree Teflon soft cannula infusion sets (6mm or 9mm), and body/pump patches, replaced every 3 days. Top-Up Kits are available for additional supplies.

6Kaleido Starter Kit
CategoryBundled Starter Kit
Description

Starter package containing two reusable Kaleido pumps (each with a 4-year warranty), one Kaleido handset, and comprehensive training and technical support.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-28
Description

Contract manufacturing partnership for commercial-scale production of Kaleido consumables. Phillips Medisize manufactures infusion sets and patches, enabling ViCentra to more than triple production capacity to support over 17,000 users.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic technology partnership for hybrid closed loop insulin delivery. Kaleido integrates with Diabeloop's DBLG1 and DBLG2 self-learning algorithms for automated insulin dosing decisions based on real-time CGM data. The partnership enables the Kaleido Hybrid Closed Loop system combining pump, CGM, and algorithm.

Strategic tierCoreTypeTechnology or Integration
Description

Technology integration for continuous glucose monitoring. Kaleido HCL system uses Dexcom G6 sensor for real-time glucose readings, with DBLG2 also supporting Dexcom G7. Integration enables automated insulin delivery adjustments.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with JDRF (Juvenile Diabetes Research Foundation) to support diabetes research and advocacy. ViCentra works with JDRF to develop ideas and improve outcomes for people with Type 1 diabetes.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Kaleido products in Germany and Netherlands. Handles product availability and logistics for patients in these markets.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Kaleido products in Germany and Netherlands. Provides product distribution and availability through local healthcare channels.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for Kaleido products in Germany. Enables local product availability and access for German patients.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of the Omnipod tubeless patch pump, the most direct competitor to Kaleido in disposable patch insulin delivery. Both companies target the same Type 1 diabetes patient pool with wearable, discreet pumps and compete for the same hybrid closed loop and smartphone-control positioning.

TypeBroad incumbent
Description

Sells the MiniMed 780G insulin pump, an established AID competitor integrated with its own Guardian CGM. Overlaps with ViCentra in the automated insulin delivery category and dominates the broader diabetes hardware market, including pediatric indications and U.S. distribution depth.

TypeDirect peer
Description

Maker of the t:slim X2 insulin pump with Control-IQ AID algorithm integrated with Dexcom CGM. Directly competes with Kaleido in the AID category, particularly for patients seeking smartphone-controlled automated insulin delivery, though Tandem's pump is tubed rather than patch-style.

TypeDirect peer
Description

European-based developer and manufacturer of patch insulin pumps (mylife Loop) using a tubeless patch form factor and integration with CamDiab AID and Dexcom CGM. Closely comparable to Kaleido in product format, target market (Type 1 diabetes), and European commercial geography.

TypeBroad incumbent
Description

Diversified diabetes device and diagnostics incumbent (Accu-Chek pumps, meters, digital tools). Competes more broadly in diabetes management rather than directly head-to-head in patch pumps, but overlaps in European reimbursement channels and target patient population.

TypeBroad incumbent
Description

Leading continuous glucose monitor (G6, G7) maker and a strategic partner of ViCentra through the Kaleido HCL system. Comparable as a core diabetes technology provider, although Dexcom's primary focus is CGM rather than insulin delivery.

TypeOthers
Description

Competes in adjacent diabetes technology via FreeStyle Libre CGM, increasingly paired with AID systems. While not an insulin pump maker, it competes for the same diabetes technology budget and increasingly enables do-it-yourself AID solutions that compete with commercial patch pumps.

TypeOthers
Description

Strategic partner of ViCentra providing the DBLG1 and DBLG2 self-learning AID algorithms integrated with Kaleido. Comparable as a diabetes AID technology provider, though its commercial model focuses on algorithm licensing rather than pump hardware.

TypeRegional player
Description

South Korea-based manufacturer of patch-style insulin pumps (Dana Diabecare) integrating with CGM systems. Comparable to ViCentra in patch form factor and AID positioning but focused primarily on Asian markets rather than competing directly in Europe or the U.S.

TypeOthers
Description

Developer of the CamAPS FX closed-loop algorithm used in AID systems including Ypsomed's mylife Loop. Comparable to Diabeloop as an algorithm partner in the AID ecosystem, relevant given the importance of AID algorithms to patch pump value propositions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ViCentra

Insulin Patch Pumps / Diabetes Management Deviceshellokaleido.com

ViCentra is a Utrecht-based medical device company that designs and commercializes the Kaleido compact, customizable insulin patch pump system for adults with Type 1 diabetes, integrating Diabeloop hybrid closed-loop algorithms and Dexcom CGM, sold via healthcare-provider prescriptions across Germany, Netherlands, and France with U.S. entry pending FDA approval.

What ViCentra does

ViCentra B.V. is a Utrecht, Netherlands-based medical device company founded in 2013 that designs, manufactures, and commercializes the Kaleido insulin patch pump system for adults with Type 1 diabetes. The flagship Kaleido pump is a compact (50x35x12.5mm, 19g), reusable, IP68-rated (1.5m for 1 hour) device available in 10 color combinations, with a 4-year warranty and a dual-wear design that supports both on-body patch and pocket wear via 5cm or 30cm tubing. The platform integrates with Diabeloop's DBLG1 and DBLG2 self-learning hybrid closed-loop algorithms and Dexcom G6/G7 continuous glucose monitors, with data managed through Diabeloop's YourLoops cloud platform and downloadable to Glooko.

ViCentra generates revenue from a Starter Kit bundle (two pumps and one handset) and high-frequency recurring consumables, including 200-unit insulin cartridges and 6mm or 9mm soft-cannula infusion sets replaced every 3 days, plus body and pump patches. The company sells exclusively through healthcare-provider prescriptions, supported by certified trainers and local medical device distributors (Mediq, TK-Pharma in Netherlands and Germany; Spezimed in Germany). Pricing is reimbursement-driven and varies by jurisdiction; Kaleido is covered by all Dutch health insurers and is eligible for reimbursement in Germany and France. The installed base grew to over 4,000 users in 2025 (doubled year-over-year), and ViCentra is preparing for U.S. market entry with an FDA filing targeted for early 2026.

ViCentra has raised approximately $200 million in total funding across a $74M Series C (December 2021, led by Partners in Equity) and a $98M Series D (initial $85M close September 2025 led by Innovation Industries, with a $13M second close in January 2026). The company employs over 200 people from 30+ nationalities and is scaling manufacturing capacity more than threefold via a partnership with Phillips Medisize to support 17,000+ users. Senior leadership includes CEO Tom Arnold (ex-Medtronic, Boston Scientific), CFO Leo Toole, CTO and co-founder Tim Oakes, and recently hired commercial leaders Karen Baxter (SVP Sales Europe, ex-Dexcom), Jay Little (VP Strategy, ex-Medtronic), and Reman McDonagh (VP Global Marketing, ex-Insulet/Medtronic/Roche/Cellnovo).

ViCentra firmographics

Firmographics
Name
ViCentra
Legal name
ViCentra B.V.
Website
https://hellokaleido.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
ViCentra is a Utrecht-based medical device company that designs and commercializes the Kaleido compact, customizable insulin patch pump system for adults with Type 1 diabetes, integrating Diabeloop hybrid closed-loop algorithms and Dexcom CGM, sold via healthcare-provider prescriptions across Germany, Netherlands, and France with U.S. entry pending FDA approval.
Ownership category
akta.pro rank

ViCentra industry classification

Industry
Product category
Insulin Patch Pumps / Diabetes Management Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAH
Infusion Sets, Catheters & Pump Consumables
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAL
Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Insulin patch pump
  • Diabetes management devices
  • Hybrid closed loop system
  • Continuous insulin delivery
  • Type 1 diabetes care

Where ViCentra is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

ViCentra business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Insulin Pump Hardware Sales: ViCentra generates revenue from the sale of reusable Kaleido insulin pumps that have a 4-year lifespan and come with a warranty. The Starter Kit includes two pumps and one handset.
  2. Consumables: Recurring revenue from consumables including insulin cartridges (200-unit capacity, replace every 3 days), infusion sets (6mm or 9mm soft cannulas), and pump/body patches. Users purchase Top-Up Kits for additional supplies.
  3. Insurance Reimbursement: Kaleido is covered by health insurance in the Netherlands and is eligible for reimbursement in Germany and France through local healthcare systems and distributors.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractKaleido Starter Kit with reusable pump and handset

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

ViCentra product offering

Product offering

Core offering

ViCentra designs, manufactures, and sells the Kaleido insulin patch pump system for adults with Type 1 diabetes. The reusable pump (50x35x12.5mm, 19g, 4-year warranty, IP68 waterproof) can be worn as a body patch or carried in a pocket via 5/30cm tubing and is available in 10 color combinations. The offering spans the stand-alone pump with Kaleido handset, the Hybrid Closed Loop system integrating Diabeloop's DBLG1/DBLG2 self-learning algorithms with Dexcom G6/G7 CGM, recurring consumables (200-unit cartridges and 6/9mm infusion sets replaced every 3 days), and the Kaleido Starter Kit bundle. Distribution flows through healthcare provider prescriptions, certified trainers, and local medical device distributors in Europe with health insurance reimbursement coverage.

Product overview

ViCentra's Kaleido is a modular insulin patch pump ecosystem consisting of the Kaleido insulin pump (core device), optional Hybrid Closed Loop add-ons (DBLG1 and DBLG2 algorithms with Dexcom CGM integration), a dedicated Kaleido handset for stand-alone use, consumables (cartridges, infusion sets, patches), and a Starter Kit bundle. The system is distinguished by its compact size, customizable color options, and flexible wear options (as patch or pocket pump with tubing). The DBLG1/DGBL2 algorithms provide AI-powered automated insulin delivery, while the standalone handset includes a bolus calculator and data sync capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Kaleido: The Kaleido insulin patch pump system - a flexible, discreet insulin delivery device available as both standalone pump and Hybrid Closed Loop system integrated with Diabeloop's DBLG1 and DBLG2 algorithms and Dexcom CGM.

Products and services

  • Kaleido Insulin Patch Pump System A compact, customizable insulin patch pump system for adults with Type 1 diabetes. Features a reusable pump with 4-year warranty, waterproof (IP68) design for 1 hour at 1.5m, 10 color combinations, dual-wear flexibility (5/30cm tubing for body patch or pocket use), and 0.05-unit pulse technology for precise dosing.
  • Kaleido Hybrid Closed Loop System (DBLG1 with Dexcom G6) Automated insulin delivery system combining the Kaleido pump with Diabeloop's DBLG1 self-learning algorithm and the Dexcom G6 CGM. Continuously monitors glucose and adjusts insulin delivery in real-time. Clinical evidence shows Time in Range improved from 57.3% to 68.8%.
  • Kaleido with DBLG2 and Dexcom G7 Next-generation smartphone-controlled Hybrid Closed Loop system combining the Kaleido pump with Diabeloop's DBLG2 self-learning algorithm and Dexcom G7 CGM sensor.
  • Kaleido Handset Reusable dedicated controller for the Kaleido stand-alone pump. Features bolus calculator (Kaleidoculator), 7 basal rate profiles, data upload to Glooko, and 1.5–2 day battery life per charge.
  • Kaleido Consumables Recurring-use consumables for the Kaleido pump system: 200-unit insulin cartridges with 5cm or 30cm tubing, 90-degree Teflon soft cannula infusion sets (6mm or 9mm), and body/pump patches, replaced every 3 days. Top-Up Kits are available for additional supplies.
  • Kaleido Starter Kit Starter package containing two reusable Kaleido pumps (each with a 4-year warranty), one Kaleido handset, and comprehensive training and technical support.

Quantifiable outcome

  • Time in Range increased from 57.3% to 68.8% after using Kaleido Hybrid Closed Loop system
  • +3 more outcomes

Companies that use ViCentra

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

ViCentra technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability2 records

Feature5 records

ViCentra partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Phillips MedisizecoreStrategic or Co-development Partner · 28 May 2026Contract manufacturing partnership for commercial-scale production of Kaleido consumables. Phillips Medisize manufactures infusion sets and patches, enabling ViCentra to more than triple production capacity to support over 17,000 users.
  • DiabeloopcoreTechnology or IntegrationStrategic technology partnership for hybrid closed loop insulin delivery. Kaleido integrates with Diabeloop's DBLG1 and DBLG2 self-learning algorithms for automated insulin dosing decisions based on real-time CGM data. The partnership enables the Kaleido Hybrid Closed Loop system combining pump, CGM, and algorithm.
  • DexcomcoreTechnology or IntegrationTechnology integration for continuous glucose monitoring. Kaleido HCL system uses Dexcom G6 sensor for real-time glucose readings, with DBLG2 also supporting Dexcom G7. Integration enables automated insulin delivery adjustments.
  • JDRFminorStrategic or Co-development PartnerCollaboration with JDRF (Juvenile Diabetes Research Foundation) to support diabetes research and advocacy. ViCentra works with JDRF to develop ideas and improve outcomes for people with Type 1 diabetes.
  • TK-PharmacoreChannel Partner/ Reseller/ DistributorDistributor for Kaleido products in Germany and Netherlands. Handles product availability and logistics for patients in these markets.
  • MediqcoreChannel Partner/ Reseller/ DistributorDistributor for Kaleido products in Germany and Netherlands. Provides product distribution and availability through local healthcare channels.
  • SpezimedcoreChannel Partner/ Reseller/ DistributorDistributor for Kaleido products in Germany. Enables local product availability and access for German patients.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

ViCentra competitors and assessment

Company assessment

Direct peers

  • Insulet Corporation: Maker of the Omnipod tubeless patch pump, the most direct competitor to Kaleido in disposable patch insulin delivery. Both companies target the same Type 1 diabetes patient pool with wearable, discreet pumps and compete for the same hybrid closed loop and smartphone-control positioning.
  • Tandem Diabetes Care: Maker of the t:slim X2 insulin pump with Control-IQ AID algorithm integrated with Dexcom CGM. Directly competes with Kaleido in the AID category, particularly for patients seeking smartphone-controlled automated insulin delivery, though Tandem's pump is tubed rather than patch-style.
  • Ypsomed: European-based developer and manufacturer of patch insulin pumps (mylife Loop) using a tubeless patch form factor and integration with CamDiab AID and Dexcom CGM. Closely comparable to Kaleido in product format, target market (Type 1 diabetes), and European commercial geography.

Broad incumbents

  • Medtronic: Sells the MiniMed 780G insulin pump, an established AID competitor integrated with its own Guardian CGM. Overlaps with ViCentra in the automated insulin delivery category and dominates the broader diabetes hardware market, including pediatric indications and U.S. distribution depth.
  • Roche Diabetes Care: Diversified diabetes device and diagnostics incumbent (Accu-Chek pumps, meters, digital tools). Competes more broadly in diabetes management rather than directly head-to-head in patch pumps, but overlaps in European reimbursement channels and target patient population.
  • Dexcom: Leading continuous glucose monitor (G6, G7) maker and a strategic partner of ViCentra through the Kaleido HCL system. Comparable as a core diabetes technology provider, although Dexcom's primary focus is CGM rather than insulin delivery.

Others

  • Abbott Diabetes Care: Competes in adjacent diabetes technology via FreeStyle Libre CGM, increasingly paired with AID systems. While not an insulin pump maker, it competes for the same diabetes technology budget and increasingly enables do-it-yourself AID solutions that compete with commercial patch pumps.
  • Diabeloop: Strategic partner of ViCentra providing the DBLG1 and DBLG2 self-learning AID algorithms integrated with Kaleido. Comparable as a diabetes AID technology provider, though its commercial model focuses on algorithm licensing rather than pump hardware.
  • CamDiab: Developer of the CamAPS FX closed-loop algorithm used in AID systems including Ypsomed's mylife Loop. Comparable to Diabeloop as an algorithm partner in the AID ecosystem, relevant given the importance of AID algorithms to patch pump value propositions.

Regional players

  • Sooil Development (Dana Diabecare): South Korea-based manufacturer of patch-style insulin pumps (Dana Diabecare) integrating with CGM systems. Comparable to ViCentra in patch form factor and AID positioning but focused primarily on Asian markets rather than competing directly in Europe or the U.S.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ViCentra social profiles

Digital presence

ViCentra compliance and trust

Trust signal

Compliance3 records

ViCentra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ViCentra leadership team

Management profile

Number of profiles

Profiles16 records

ViCentra funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ViCentra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViCentra

What does ViCentra do?

ViCentra designs, manufactures, and sells the Kaleido insulin patch pump system for adults with Type 1 diabetes. The reusable pump (50x35x12.5mm, 19g, 4-year warranty, IP68 waterproof) can be worn as a body patch or carried in a pocket via 5/30cm tubing and is available in 10 color combinations. The offering spans the stand-alone pump with Kaleido handset, the Hybrid Closed Loop system integrating Diabeloop's DBLG1/DBLG2 self-learning algorithms with Dexcom G6/G7 CGM, recurring consumables (200-unit cartridges and 6/9mm infusion sets replaced every 3 days), and the Kaleido Starter Kit bundle. Distribution flows through healthcare provider prescriptions, certified trainers, and local medical device distributors in Europe with health insurance reimbursement coverage.

Is ViCentra a public or private company?

ViCentra is a private company. It is classified as venture growth investor backed and is currently operating.

When was ViCentra founded?

ViCentra was founded in 2013. It employs 101 to 250 people.

Where is ViCentra based?

ViCentra is headquartered in Utrecht, Netherlands, in the Europe region.

How does ViCentra make money?

Three revenue lines are on record. Insulin Pump Hardware Sales are the primary driver. The others are consumables and insurance Reimbursement.

Who are ViCentra's main competitors?

Direct peers on record are Insulet Corporation, Tandem Diabetes Care and Ypsomed. Broad incumbents are Medtronic, Roche Diabetes Care and Dexcom. Others are Abbott Diabetes Care, Diabeloop and CamDiab. Sooil Development (Dana Diabecare) is listed as a regional player.

Does ViCentra have an API?

No public API is recorded for ViCentra.

What industry is ViCentra in?

ViCentra's product category is Insulin Patch Pumps / Diabetes Management Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 339113 and its SIC code is 5047.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical BuyerViCentra names Ian Wells as CFO, appoints Tom West to boardViCentra announced the appointment of Ian Wells as Chief Financial Officer effective June 19, 2026, and Thomas A. West to its Board of Directors effective July 1, 2026, as the company seeks to accelerate European growth and prepare for US market entry. The appointments follow ViCentra's $98 million Series D financing and commercial-scale production launch of its Kaleido smartphone-controlled insulin delivery system. The new leadership brings deep financial and strategic expertise to support ViCentra's expansion beyond its current base of over 5,000 users in Germany, the Netherlands, and France.GlobeNewswireViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its BoardViCentra, a Dutch medical device company commercializing the Kaleido insulin patch pump system, appointed Ian Wells as Chief Financial Officer effective June 19, 2026, and Thomas A. West as an Independent Board Member effective July 1, 2026. Wells brings nearly two decades of medtech finance leadership from his role as Global CFO of HOYA Vision Care, while West joins with a track record of leading two medtech companies to acquisitions totaling $1.7 billion. The appointments are designed to build on ViCentra's recent $98 million Series D financing, commercial-scale manufacturing at Phillips Medisize, and existing user base of over 5,000 patients across Germany, the Netherlands, and France as the company prepares for U.S. market entry.FinancialContent Business PageDiabeloop and ViCentra Launch Smartphone-Controlled DBLG2 System Integrated with Kaleido Insulin Patch Pump and Dexcom G7 CGM, Now Open for PrescriptionDiabeloop announced the commercial launch of its DBLG2 Automated Insulin Delivery system integrated with ViCentra's Kaleido insulin patch pump and Dexcom G7 CGM, now open for prescription in Germany with Netherlands rollout planned for later summer 2026. The smartphone-based system eliminates the need for a dedicated handset and leverages real-world clinical data showing >77% Time in Range and 0.2% Time Below Range among users. Following CE marking approval, the rollout marks Diabeloop's strategic transition toward a pure software, patient-centric model with an iOS version also in development.GoogleViCentra Kaleido with G7, DBLG2 is now available, Diabeloop saysDiabeloop announced its DBLG2 automated insulin delivery algorithm is now open for prescription with Dexcom G7 and ViCentra Kaleido, available in Germany with Netherlands availability soon. The system adjusts insulin every five minutes and requires no meal announcements. Diabeloop is processing prescriptions through distributor networks in Germany.TechRoundTop Deep Tech Startups In The NetherlandsThe Netherlands has established itself as one of Europe's most significant deep tech hubs, anchored by the presence of ASML and supported by decades of industrial research infrastructure, university spin-out pipelines, and engineering talent concentrated in Eindhoven, Delft, and Amsterdam. The Dutch government has reinforced this positioning through the Deep Tech Fund, which channels capital into high-risk technology companies that commercial VCs find difficult to price, with recent expansion signaling continued public commitment. The article profiles eight Dutch deep tech startups spanning semiconductors, quantum computing, advanced materials, energy storage, industrial automation, and medtech, including Axelera AI, Nearfield Instruments, QuantWare, LeydenJar Technologies, ViCentra, Accerion, Newton Energy Solutions, and VSPARTICLE.GoogleViCentra CEO explains how Kaleido competes with 'handbrake off,'ViCentra announced a manufacturing capacity expansion with Phillips Medisize, tripling supply from 5,000 to over 17,000 users. CEO Tom Arnold said the partnership enables aggressive European expansion and U.S. market entry by late next year. The company also launched its smartphone-controlled Kaleido insulin pump in Europe.GoogleViCentra triples manufacturing capacity ahead of Kaleido rolloutViCentra began commercial-scale production of its Kaleido insulin pump consumables with Phillips Medisize, tripling capacity to support over 17,000 users. The expansion targets adding thousands of new users across Germany, the Netherlands, and France in the second half of 2026. The company also plans to accelerate preparations for a U.S. market launch.GlobeNewswireViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit EconomicsViCentra announced the start of commercial-scale production of Kaleido consumables at Phillips Medisize, a contract manufacturing organization, more than tripling its production capacity with initial scale to support over 17,000 users. The expanded supply positions ViCentra to add thousands of new users across Germany, the Netherlands, and France through the second half of 2026, with Germany representing the world's second-largest insulin pump market. The volume manufacturing partnership is expected to anchor ViCentra's long-term unit economics and accelerate growth across Europe.BioSpaceViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit EconomicsViCentra began commercial-scale production of Kaleido consumables at Phillips Medisize, tripling capacity to support over 17,000 users. The expansion aims to add thousands of new users across Germany, the Netherlands, and France through the second half of 2026, with Germany representing the world's second-largest insulin pump market.GoogleViCentra launches smartphone-controlled Kaleido automated insulin patch pump systemViCentra launched its Kaleido smartphone-controlled hybrid closed-loop insulin delivery system in Europe, combining its patch pump with Diabeloop's DBLG2 algorithm and Dexcom G7. The system follows Diabeloop's CE mark for the algorithm and G7, and ViCentra says starting on the previous-generation DBLG1 and G6 remains the fastest path to the next-generation combination.